Our broader aim is to investigate the molecular perturbations involved in CVDs such as hypertension, vascular dysfunction, atherosclerosis, thrombosis, and ischemia- and hypertension-induced cardiac remodeling and heart failure. Moreover, considering several structural and functional similarities in cardiac and skeletal muscles, CVR group is additionally focusing on investigating the potential molecular mechanisms causing the coupling of cardiac and skeletal muscle dysfunction. We will meet our aims with the following specific objectives:
Identify genes and genetic defects and, delineate the underlying molecular mechanisms to enhance our understanding of CVDs including various types of cardiomyopathies, thrombotic and vascular disorders including endothelial dysfunction, familial hypercholesterolemia and inherited bleeding disorders.
Perform detailed phenotypic and molecular characterization of patients with major CVDs.
Establish potential circulating biomarkers for early risk assessment and treatment of CVDs.
Identify and characterize the novel drug targets employing in vitro and in vivo mouse models.
Delineate the molecular mechanisms causing coupling of cardiac and skeletal muscle dysfunction and, evaluate the effects of microgravity on cardiovascular remodeling.
Screen the small molecule inhibitors to design better therapies against CVDs.
Investigate the immunopharmacological interventions related to renal and cardiovascular disorders.